Scientific briefing: Dissolution development Parvulet technology with oral tablets
Posted: 7 July 2021 | ADARE Pharma Solutions | No comments yet
Parvulet™ Technology is a patented oral dosage form capable of being dispensed to patients in tablet or powders, and converted into a semi-solid with water.
The final dosage is easily administered, as a soft food like texture, ideal for paediatric and geriatric populations. The Parvulet technology can be combined with our taste-masking and controlled release technologies, providing greater flexibility in advancing patient centric solutions.
Related content from this organisation
- EPR Podcast Episode 26 – Navigating Nitrosamine Impurities – Jason Brown, Adare Pharma Solutions
- Maintaining EU MDR certification: a spotlight on post‑market clinical follow-up
- Formulation, Development & Delivery In-Depth Focus 2021
- Scientific briefing: Formulation-Monodisperse CR quetiapine microspheres
- Scientific briefing: Formulation of aqueous core poly (lactic acid) microcapsules
Related topics
Analytical techniques, Biopharmaceuticals, Excipients, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Research & Development (R&D)